1. Home
  2. QSI vs MSLE Comparison

QSI vs MSLE Comparison

Compare QSI & MSLE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Quantum-Si Incorporated

QSI

Quantum-Si Incorporated

HOLD

Current Price

$0.76

Market Cap

165.3M

Sector

Health Care

ML Signal

HOLD

MSLE

Satellos Bioscience Inc. Common Stock

N/A

Current Price

$6.19

Market Cap

146.9M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
QSI
MSLE
Founded
2013
N/A
Country
United States
Canada
Employees
145
17
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
165.3M
146.9M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
QSI
MSLE
Price
$0.76
$6.19
Analyst Decision
Buy
Analyst Count
2
0
Target Price
$1.00
N/A
AVG Volume (30 Days)
2.9M
103.1K
Earning Date
03-03-2026
N/A
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$618.07
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.79
$6.67
52 Week High
$3.10
$13.39

Technical Indicators

Market Signals
Indicator
QSI
MSLE
Relative Strength Index (RSI) 33.04 26.32
Support Level N/A N/A
Resistance Level $1.11 $8.37
Average True Range (ATR) 0.06 0.88
MACD -0.01 -0.21
Stochastic Oscillator 0.88 2.25

Price Performance

Historical Comparison
QSI
MSLE

About QSI Quantum-Si Incorporated

Quantum-Si Inc is a life sciences company focused on proteomics research and analytical technologies. It develops single-molecule detection platforms designed to enable next-generation protein sequencing (NGPS) and large-scale protein analysis. Its technology supports massively parallel sequencing of proteins and can also be applied to the study of nucleic acids, providing tools for researchers and clinical applications in molecular analysis. The company's revenue is derived from sales of products and services.

About MSLE Satellos Bioscience Inc. Common Stock

Satellos Bioscience Inc is a regenerative medicine company a biotechnology and drug development company. The company is developing novel therapeutics that stimulate or restore muscle regeneration in severe disorders. The company's program is focused on developing an oral therapeutic drug for Duchenne muscular dystrophy that serves to correct this dysregulation which Satellos has identified as a root cause of the progressive nature of this disease.

Share on Social Networks: